

Pharmacy Drug Policy Checklist

POLICY NAME Vyjuvek (beremagene geperpavec) POLICY # 3205P

Criteria

Coverage Criteria	
	Diagnosis of dystrophic epidermolysis bullosa (DEB) confirmed by gene testing • Gene testing must be submitted to support pathogenic mutations in COL7A1 gene
	Documentation to support open skin wounds • Application is limited to open skin wounds only
	Age 6 months or older
	Prescribed by or in consultation with a dermatologist (skin doctor) who specializes in epidermolysis bullosa management
	Clinical review of documentation confirming that patient has met all of the above requirements for treatment completed by both a pharmacist and medical director
Exclusion Criteria – Any of the following prevents coverage	
	History of squamous cell carcinoma or actively receiving cancer treatment
	History of skin graft within previous 3 months